What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014

Visco, Anthony G.; Fraser, Matthew O.; Newgreen, Donald; Oelke, Matthias; Cardozo, Linda

doi:10.1002/nau.22795

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For patients experiencing inadequate control with antimuscarinic or Mirabegron monotherapy alone, combination therapy may offer greater efficacy 18,39 without an increased safety risk 40 …”

Section: What Is the Role Of Combination Therapy?mentioning

confidence: 99%

“…For patients experiencing inadequate control with antimuscarinic or Mirabegron monotherapy alone, combination therapy may offer greater efficacy 18,39 without an increased safety risk. 40 Recently, several large clinical studies have investigated the value of combining Solifenacin and Mirabegron treatments. [41][42][43][44] The European, Phase II, randomised, double-blind, parallel-group, placebo-and monotherapy-controlled SYMPHONY study evaluated the efficacy of combinations of Solifenacin/Mirabegron compared with Solifenacin 5 mg monotherapy over 12 weeks.…”

Section: What Is the Role Of Comb Inati On Ther Apy ?mentioning

confidence: 99%

See 1 more Smart Citation

Shifting the treatment paradigm in idiopathic overactive bladder

et al. 2021

View full text Add to dashboard Cite

Summary Purpose Overactive Bladder (OAB) is a common condition that is known to have a significant impact on Health Related Quality of Life (HRQoL). Whilst all patients will initially benefit from lifestyle modifications and behavioural therapy in the first instance drug therapy remains integral in management pathways. The purpose of this review paper is to reappraise the evidence based approach to the management of OAB in addition to exploring a new treatment algorithm for the escalation of treatment in those patients with refractory symptoms. Design Literature Review Results Antimuscarinic drugs are currently the most commonly used medication although the introduction of mirabegron, a β3 agonist, has provided an alternative and also allowed combination therapy in those patients who have failed to improve on primary therapy or who have troublesome side effects. For those patients with symptoms of refractory OAB more invasive therapies including OnabotulinumtoxinA, sacral neuromodulation and Percutaneous Tibial Nerve Stimulation (PTNS) may be indicated. Conclusion We propose a new, evidence based, treatment algorithm for the management of OAB in patients who remain refractory to first line therapy.

show abstract

“…For patients experiencing inadequate control with antimuscarinic or Mirabegron monotherapy alone, combination therapy may offer greater efficacy 18,39 without an increased safety risk 40 …”

Section: What Is the Role Of Combination Therapy?mentioning

confidence: 99%

Section: What Is the Role Of Comb Inati On Ther Apy ?mentioning

confidence: 99%

Shifting the treatment paradigm in idiopathic overactive bladder

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Several combinations have been reported. Some of them were based on pharmacotherapy, with a single additional therapy [ 5 ]; while some of them used two drugs [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study

Zhang

Wang

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Objective We evaluated a combination of transcutaneous electrical nerve stimulation (TENS) and solifenacin succinate versus solifenacin alone in the treatment of overactive bladder (OAB). Methods Ninety-seven female outpatients with OAB were screened for this double-blind randomized controlled study. Eighty-six patients who met our inclusion criteria were divided randomly into two groups. In group A (43 patients), patients received oral solifenacin and “fake” TENS on the foot; in group B (43 patients), patients received oral solifenacin and effective TENS on the foot. Improvements in OAB symptoms were assessed by Overactive Bladder Symptom Score (OABSS), Overactive Bladder Questionnaire (OAB-q), voiding diaries and urodynamic tests. 70 of 86 patients (36 in group A, 34 in group B) completed the 2 months of treatment and 3 months of follow-up. Results Statistically, the maximum bladder volume and OAB symptoms of both groups improved significantly after treatment. The improvement in group B was significantly better than that in group A, as indicated by the maximum bladder volume, OAB-q score and voiding diary. Some mild adverse effects were observed, including dry mouth, stomach upset, constipation, muscle pain and local paresthesia. Conclusion The combination of TENS and solifenacin was more effective in improving OAB symptoms than solifenacin alone.

show abstract

UDS in Overactive Bladder Syndrome (OAB-S)

Vignoli

2018

Urodynamics for Urogynecologists

View full text Add to dashboard Cite

What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014

Cited by 6 publications

References 24 publications

Shifting the treatment paradigm in idiopathic overactive bladder

Shifting the treatment paradigm in idiopathic overactive bladder

Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study

UDS in Overactive Bladder Syndrome (OAB-S)

Contact Info

Product

Resources

About